OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.

Livestock breeders could soon have more tools to improve the health and quality of their animals, thanks to a recent study ...

An expert involved in the first successful gene therapy trial for Huntington's Disease discusses the trial results and ...

Genetic switches near the FTO locus may enable hibernators’ extreme metabolic resilience and could inspire future treatments ...

A study has traced thousands of conserved regulatory elements back 300 million years, revealing deep principles of plant genome evolution—a discovery that could pave the way for more precise ...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 Earnings Call Transcript March 19, 2026 Taysha Gene Therapies, Inc. beats earnings expectations. Reported EPS is $-0.08711, expectations were ...

The last available hemophilia gene therapy is temporarily unavailable, according to CSL Behring.  | The company is working ...

Advanced commercial readiness by appointing gene therapy veteran Brad Martin to lead market access, focusing on early payer ...

Tools like CRISPR-Cas9 are creating new opportunities for innovation in St. Louis, as well as risks around IP protection and regulation.

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.

The announcement that the UK and the EU are moving towards a new Sanitary and Phytosanitary (SPS) agreement represents, in Professor Chris Elliott’s opinion, one of the most significant developments ...